A retired surgeon says the fix for blurry vision is already in your kitchen

The Retina Sits Behind Two Barriers

Nothing here is a reason to start or stop any treatment, supplement or prescribed medication. Those decisions belong with a clinician who knows the case. What follows concerns how substances reach the back of the eye, which is a question of anatomy and pharmacology and has well-documented answers.

The retina is among the most thoroughly defended tissues in the body. It sits behind two separate barriers, each formed by a continuous sheet of cells joined by tight junctions, and their combined effect is that most of what circulates in the blood never reaches the photoreceptors at all.

The inner barrier is formed by the endothelial cells lining the retinal blood vessels. Unlike vessels elsewhere, these have no gaps between cells and no windows through them, and they are supported by pericytes and by specialized glial cells that maintain the arrangement. The structure is closely analogous to the barrier protecting the brain.

The outer barrier is formed by the retinal pigment epithelium, a single layer of cells sitting between the retina and the vascular bed that supplies it from behind. These cells are likewise sealed to one another, and everything moving from that blood supply into the retina passes through them rather than between them.

The consequence is a size limit and a selectivity rule. Retinal vessels are described in the reference literature as impermeable to molecules above roughly twenty to thirty thousand daltons. What does cross is either small and lipid-soluble enough to pass through membranes, or carried by a specific transporter built for it — glucose by one, particular amino acids by others.

Everything else is excluded, and a family of efflux pumps in both barriers actively returns a range of molecules to the blood after they have entered, which is a further filter operating on precisely the compounds most likely to arrive by accident.

This is why delivering medicine to the retina is one of the harder problems in pharmacology, and why the treatments that do reach it are given by injection into the eye rather than swallowed.

What follows is the two barriers and what forms them, why an oral dose is not a delivered dose, how the drugs that do reach the retina get there, what has actually been measured in the eye, and what a delivery claim would have to show.

The Two Barriers and What Forms Them

The architecture is worth holding precisely, because the two barriers guard different approaches and fail in different diseases.

The retina has two blood supplies. The central retinal artery feeds the inner layers through vessels running within the retina itself. The choroid, a dense vascular bed behind the retina, supplies the outer layers including the photoreceptors.

The inner barrier guards the first. Its endothelial cells are joined by tight junctions, lack the fenestrations that make most capillaries leaky, and rest on a continuous basement membrane with pericytes wrapped around them.

The outer barrier guards the second. The choroidal vessels are in fact quite leaky, which would matter enormously were it not for the pigment epithelium sitting between them and the retina, sealed cell to cell.

Both barriers are maintained actively rather than passively. The supporting glial cells signal to the endothelium to keep the junctions tight, which is why disruption of those cells appears early in several retinal diseases.

That last point is the clinically important one. Barrier breakdown is a feature of disease rather than a route to treatment: when the barrier leaks, fluid enters the retina where it does not belong, and the resulting swelling is itself a major cause of vision loss.

Why an Oral Dose Is Not a Delivered Dose

The distance between swallowing something and it arriving at a tissue involves several stages, each of which removes most of what started.

Absorption is the first stage. A compound must survive the stomach, dissolve, and cross the intestinal wall. Many plant compounds are poorly soluble and poorly absorbed, and a large fraction of a swallowed dose never enters the bloodstream at all.

First-pass metabolism is the second. Blood from the intestine goes to the liver before it goes anywhere else, and the liver chemically modifies foreign compounds efficiently. Many are converted to water-soluble forms and excreted, which is the liver doing exactly its job.

Distribution is the third. Whatever survives is diluted into the whole circulating volume and distributed across every tissue according to blood flow and affinity. The eye is small and receives a correspondingly small share.

The barrier is the fourth and, for the retina, the decisive one. A compound that has survived the first three stages still has to cross a sealed cell layer, and the great majority do not.

Each stage multiplies. A compound with modest absorption, substantial first-pass loss, wide distribution and no barrier transport can arrive at the retina at a concentration many orders of magnitude below what produced an effect in a laboratory dish.

That gap between the dish and the tissue is the single most common unstated assumption in claims of this kind.

How Drugs That Do Reach the Retina Get There

The treatments that work on retinal disease illustrate the problem by the lengths they go to.

The principal treatments for the leading causes of central vision loss are large protein molecules, far above the size that crosses either barrier, and they are administered by injection directly into the vitreous cavity of the eye.

That route exists precisely because no other reliably works. It places the drug inside the barrier rather than asking it to cross, and it is repeated at intervals because the drug clears.

Implants releasing medication slowly inside the eye follow the same logic. So do the surgical and laser approaches, which act on the tissue directly.

Where systemic administration is used in eye disease, it is generally for conditions of the ocular surface, the orbit or inflammation involving structures outside the barrier, or for infections where very high blood concentrations are achievable.

Research into systemic delivery to the retina is active and is framed, in the literature itself, as an effort to overcome the barrier — by targeting the transporters that do exist, by temporarily modulating the junctions, or by designing molecules that exploit a known carrier. That framing is the clearest statement available that the default is exclusion.

What Has Actually Been Measured in the Eye

The empirical question — what concentration of a given compound appears in retinal tissue after an oral dose — has an established experimental answer for a small number of substances and no answer at all for most.

The measurement requires tissue, which in humans means eyes obtained after death or during surgery, and this is why the human data is sparse and the animal data is more extensive.

The clearest human evidence concerns the carotenoids concentrated in the central retina. These are taken up selectively by specific binding proteins, accumulate measurably in the macula, and their density can be measured non-invasively. Supplementation raises that measured density, which is a genuine demonstration of delivery to the tissue.

That case is instructive precisely because it is unusual. It works because a dedicated transport and binding system exists for those molecules, and the existence of that system is the exception rather than the rule.

For most compounds proposed as retinal remedies, no comparable measurement has been published. That absence is not proof of failure, and it is the specific evidence that would be required, and its absence should be noticed rather than filled in.

The general principle is that a demonstration of effect in cultured cells establishes that a compound can act on those cells at the concentration used, and says nothing about whether that concentration is achievable in a living retina by any route.

What a Delivery Claim Would Have to Show

The questions that resolve a claim in this area are few, and they can be asked without any specialist knowledge.

The first is whether the compound was shown to reach the tissue, at what concentration, and by what measurement.

The second is whether the concentration reached corresponds to the concentration that produced the effect in whatever experiment is being cited. A dish experiment states its concentration, and comparing the two numbers is arithmetic.

The third is what the outcome measure was. A change in a laboratory marker is not a change in vision, and vision measured under different conditions before and after is not a comparison.

The fourth is whether there was a control group. Vision fluctuates, chart performance improves with familiarity, and several retinal conditions have a natural history that includes spontaneous improvement.

The fifth is whether the institution named in a claim published anything. Research institutions maintain public listings of their publications, and an attribution that cannot be traced to a paper is an attribution to a name rather than to a finding.

The composite point is that the retina is behind two sealed cell layers that exclude most of what circulates, that the treatments which work are injected past them, and that a claim of oral delivery to this particular tissue is a strong claim requiring the specific evidence that measurement in the eye provides.